Chemokines and disease

Nature Immunology

Volumn 2, Issue 2, 2001, Pages 108-115

  Gerard, Craig ^a   Rollins, Barrett J ^b,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ALLOTRANSPLANTATION; ANIMAL; ASTHMA; DISEASE MODEL; HISTOCOMPATIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MULTIPLE SCLEROSIS; NEOPLASM; REVIEW; RHEUMATOID ARTHRITIS; VASCULAR DISEASE;

ANIMALS; ARTHRITIS, RHEUMATOID; ASTHMA; CHEMOKINES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HIV INFECTIONS; HUMANS; MULTIPLE SCLEROSIS; NEOPLASMS; RECEPTORS, CHEMOKINE; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS; VASCULAR DISEASES;

EID: 0035260881     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/84209     Document Type: Review

References (118)

1. Thelen, M. Dancing to the tune of chemokines. Nature Immunol. 2, 129-134 (2000).
2. Rollins, B. J. Chemokines. Blood 90, 909-928 (1997).
3. Katoh, S. et al. Elevated chemokine levels in bronchoalveolar lavage fluid of patients with esoinophilic pneumonia. J. Allergy Clin. Immunol. 106, 730-736 (2000).
4. Butterfield, R. J. et al. Identification of genetic loci controlling the characteristics and severity of brain and spinal cord lesions in experimental allergic encephalomyelitis. Am. J. Pathol. 157, 637-645 (2000).
5. Ransohoff, R. M. Chemokines and chemokine receptors in model neurological pathologies: molecular and immunocytochemical approaches. Meth. Enzymol. 287, 319-348 (1997).
6. Karpus,W.J. & Kennedy, K.J. MIP-Iα and MCP-I differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J. Leukoc. Biol. 62, 681-687 (1997).
7. Glabinski,A. R.,Tani, M.,Tani, M., Tuohy,V.K. Tuthill, R.J. & Ransohoff, R. M. Central nervous system chemokine mRNA accumulation follows initial leukocyte entry at the onset of acute murine experimental autoimmune encephalomyelitis. Brain. Behav. Immunol. 9, 315-330 (1995).
8. Karpus,W. J. et al An important rote for the chemokine macrophage inflammatory protein-1 α in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J. Immunol. 155, 5003-5010 (1995).
9. Godiska, R., Chantry, D., Dietsch, G. N. & Gray, P.W. Chemokine expression in murine experimental allergic encephalomyelitis. J. Neuroimmunol. 58, 167-176 (1995).
10. Ransohoff, R. M. et al. Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. FASEB J. 7, 592-600 (1993).
11. Tran, E. H., Kuziel,W.A, & Owens,T. Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1 α or its CCRS receptor. Eur. J. Immunol. 30, 1410-1415 (2000).
12. Rottman, J. B. et al. Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCRI dependent. Eur J. Immunol. 30, 2372-2377 (2000).
13. Fife, B.T., Huffnagle, G. B., Kuziel,W.A. & Karpus, W.J. CC Chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J. Exp. Med. 18, 899-906 (2000).
14. Izikson, L, Klein, R. S., Charo, I. F.,Weiner. H. L & Luster, A. D. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J. Exp. Med. 192, 1075-1080 (2000).
15. Boring, L et al. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin Invest. 100, 2552-2561 (1997).
16. H2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404, 407-411 (2000).
17. Miyagishi, R., Kikuchi, S., Fukazawa,T. & Tashiro, K. Macrophage inflammatory protein-1 α in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. J. Neurol. Sci 129.223-227 (1995).
18. McManus. C. et al. MCP-1, MCP-2 and MCP-3 expressions in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J.Neuroimmunol, 86, 20-29 (1998).
19. Simpson, J. et al. Expression of the β-chemokine receptors CCR2, CCR3, and CCR5 in multiple sclerosis central nervous system tissue. J. Neuroimmunol. 108, 192-200 (2000).
20. Balashov, K.E., Rottman, J.B.,Weiner, H.L & Hancock, W.W. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-α and IP-10 are expressed in demyelinating brain lesions. Proc. Natl Acod. Sci USA 96, 6873-6878 (1999).
21. Sorensen,T. L et of. Expressions of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103, 807-815 (1999).
22. Iarlori, C. et al. RANTES production and expression is reduced in relapsing-remitttng multiple sclerosis patients treated with interferon-β-1b.J. Neuroimmunol. 10, 100-107 (2000).
23. Bennetts, B. H.,Teutsch, S. M.. Buhler, M. M., Heard. R. N. & Stewart. G. J.The CCR5 deletion mutation fails to protect against multiple sclerosis.Hum.Immunol. 58, 52-59 (1997).
24. Barcellos, L F et al. CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics 51, 281-288 (2000).
25. Hancock,W. W, Gao.W, Faia, K-L & Csizmadia,V. Chemokines and their receptors in allograft rejection. Curr. Opin. Immunol. 12, 511-516 (2000).
26. Melter, M., McMahon, G., Fang, J., Ganz, P. & Briscoe, D. M. Current understanding of chemokine involvement in allograft transplantation. Pediatr.Transplant. 3, 10-21 (1999).
27. Yun, J. J. et al. Early and late chemokine production correlates with cellular recruitment in cardiac allograft vasculopathy. Transplantation 69, 2515-2524 (2000).
28. Belperio, J. A, et al. The role of the CC chemokine, Rantes, in acute lung allograft rejection. J. Immunol. 461,72 (2000).
29. Kapoor,A. et al. Intragraft expression of chemokine gene occurs early during acute rejection of allogeneic cardiac grafts. Transpl. Proc, 32, 793-795 (2000).
30. Watarai, Y. et al. Intraallograft chemokine RNA and protein during rejection of MHC-matched/multiple minor histocompatibiliry-disparate skin grats. J. Immunol. 164, 6027-6033 (2000).
31. Kapoor, A. et al. Early expression of interferon-γ inducible protein 10 and monokine induced by interferon-γ in cardiac allografts is mediated by CD8+T cells.Transplantation 69, 1147-1155 (2000).
32. Kondo, T. et. al. Early increased chemokine expression and prodcution in murine allogeneic skin grafts is mediated by natural killer cells. Tranplantation 69, 969-977 (2000).
33. Gao,W. et al. Targeting of the chemokine receptor. CCRI, suppresses development of acute and chronic cardiac allograft rejection. J. Clin. Invest. 105, 35-44 (2000).
34. Hancock, W.W. et al. Requirements of the chemokine receptor CXCR3 for acute allograft rejection. J. Exp. Med. 192, 1515-1520 (2000).
35. Hl polarization.Nature Immunol. 1, 305-310 (2000).
36. Shimizu, K., Schonbeck, U., Mach, F., Libby, P. & Mitchell, R. N. Host CD40 ligand deficiency induces long-term allograph survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J. Immunol. 165, 3506-3518 (2000).
37. Tellides. G. et al. Interferon-γ elicits arteriosclerosis in the absence of leukocytes. Nature 403, 207-211 (2000).
38. Berger, E.A., Murphy, P.M. & Farber.J. M.Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17, 657-700 (1999).
39. Wu, L. et al. CD4-induced interaction of primary HIV-1 gp 120 glycoproteins with the chemokine receptor CCR-5. Nature 384, 179-183 (1996).
40. Trkola, A. et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384,184-187 (1996).
41. Blanpain, C. et al. Multiple nonfunctional alleles of CCR5 are frequent in various human populations. Blood 96, 1638-1645 (2000)
42. Palacios, E, et at Parallel evolution of CCR5-null phenotypes in humans and in a natural host of simian immunodeficiency virus. Curr. Biol. 8, 943-946 (1998).
43. Petrek, M. et al. CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. Am. J.Respir. Crit. Care Med. 162, 1000-1003 (2000).
44. Tuttle, D. L. Harrison. J. K., Andres, C., Sleasman, J.W & Goodenow. M. M. Expressions of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1. J. Virol. 72, 4962-4969 (1998).
45. th Conference on Retroviruses and Opportunistic Infections.Abstr.S17 (2000).
46. Lamkhioued, B. et al. Monocyte chemoattractant protein (MCP)-4 expressions in the airways of patients with asthma. Induction in epithelial cells and mononuclear cells by proinflammatory cytokines. Am. J. Respir. Crit. Care Med. 162, 723-732 (2000).
47. Sekiya,T. et al. Inducible expresion of a Th2-type CC chemokine thymus- and activation-regulated chemokine by human bronchial epithelial cells. J. Immunol. 165, 2205-2213 (2000).
48. Ying, S. et al. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4). and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. J. Immunol. 163, 6321-6329 (1999).
49. Gonzalo. J.A, et al. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J. Exp. Med. 188, 157-167 (1998).
50. Elsner. J. et al The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCRI and CCR3. Eur J. Immunol. 27, 2892-2898 (1997).
51. Dabbagh, K. et al. Local blockage of allergic airway hyperreactivity and inflammation by the poxvirus-derived pan-CC-chemokine inhibitor vCCI. J. Immunol. 165, 3418-3422 (2000).
52. Lloyd, C. M. et al. CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monoeyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo. J. Exp. Med. 19, 265-274 (2000).
53. H2 cells. J.Immunol. 161, 547-551 (1998).
54. D'Ambrosio, D. et al. Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2Th cells. J. Immunol. 161, 5111-5115 (1998).
55. Gong, J. H., Ratkay. LG.,Waterfield, J. D. & Clark-Lewis, I.An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-1pr mouse model. J.Exp. Med. 186, 131-137 (1997).
56. Ogata, H.,Takeya, M.,Yoshimura,T.,Takagi, K. & Takahashi, K. The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. J. Pothol. 182, 106-114 (1997).
57. Plater-Zyberk, C, Hoogewerf, A. J., Proudfoot,A. E., Power, C.A. & Wells,T. N. Effect of a CC chemokine receptor antagonist on coflagen induced arthritis in DBA/I mice. Immunol. Lett 57, 117-120(1997).
58. De Benedetti, F. et al, Interleukin 8 and monocyte chemoattractant protein-1 in patients with juvenile rheumatoid arthritis. Relation to onset types, disease activity, and synovial fluid leukocytes. J. Rheumotol. 26, 425-431 (1999).
59. Al-Mughales, J., Blyth,T. H., Hunter, J.A. & Wilkinson, P. C.The chemoattractant activity of rheumatoid synovial fluid for human lymphocytes is due to multiple cytokines. Clin. Exp. Immunol. 106, 230-236 (1996).
60. Buckley, C. D. et al. Persistent induction of the chemokine receptor CXCR4 by TGF-β1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J. Immunol. 165, 3423-3429 (2000).
61. Konig, A., Krenn, V., Toksoy, A., Gerhard, N. & Gillitzer, R. Mig, GROα and RANTES messenger RNA expression in lining layer, infiltrates and different leucocyte populations of synovial tissue from patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Virchows Arch. 436, 449-458 (2000).
62. Taylor, P. C. et al Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arthritis Rheum. 43, 38-47 (2000).
63. - memory T cells in rheumatoid arthritis synovium. Arthiritis Res. 2, 415-423 (2000).
64. Wedderburn, L R., Robinson, N., Patel, A.,Varsani, H. & Woo, P. Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. Arthritis Rheum. 43, 765-774 (2000).
65. Qin, S. et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest 101, 746-754 (1998).
66. Gomez-Reino, J. J. et al. Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. Arthirits Rheum. 42, 989-992 (1999).
67. Garred, P. et al. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J. Rheumotol. 25, 1462-1465 (1993).
68. Virchow, R. Die krankhaften Geschwulste. Dreißig Vorlesungen, gehalten während des Wintersemesters 1862-1863 an der Universität zu Berlin (Verlag von August Hirschwald. Berlin, 1863).
69. Bashford, E F, in Scientific Reports on the Investigations of the ICRF (eds Bashford, E. F., Murray, J.A. & Cramer,W) (ICRF. London, 1905).
70. Russell, B. R. G.The nature of resistance to the inoculation of cancer. Sci. Rep. ICRF 3, 341-358 (1908).
71. Carrel, A. Growth-promoting function of leukocytes. J. Exp. Med. 36, 385-391 (1922).
72. Bottazzi, B. et al. Regulation of the macrophage content of neoplasms by chemoattractant. Science 220, 210-212 (1983).
73. Bottazzi, B. et al. Tumor-derived chemotactic factor(s) from human ovarian carcinoma: evidence for a role in the regulation of macrophage content of neoplastic tissues. Int. J. Cancer 36, 167-173 (1985).
74. Negus. R. P., Stamp, G.W, Hadley, J. & Balkwill, F. R. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines.Am. J. Pathol. 150, 1723-1734 (1997).
75. Walter, S., Bottazzi, B., Govoni, D., Colotta, F & Macrophage, A. Macrophage infiltration and growth of sarcoma clones expressing different amounts of monocyte chemotactic protein/JE. J.Int. J. Cancer 49, 431-435 (1991).
76. Leek. R. D. et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56, 4625-4629 (1996).
77. Ueno,T. et at Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis. and survival in human breast cancer. Clin. Cancer Res. 6, 3282-3289 (2000).
78. Kleine-Lowinski, K., Gillitzer, R., Kuhne-Heid, R. & Rosl, F. Monocyte-chemo-attractant-protein-1 (MCP-1)-gene expression in cervical intra-epithelial neoplasias and cervical carcinomas. Int. J. Cancer 82, 6-11 (1999).
79. Rollins, B. J. & Sunday, M. E. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol. Cell Biol. 11, 3125-3131 (1991).
80. Bottazzi, B., Walter, S., Govoni, D., Colotta, F. & Mantovani, A. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J. Immunol. 148, 1280-1285 (1992).
81. Manome,Y. et al. Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors. Cancer Immunol. Immunother. 41, 227-235 (1995).
82. Mule, J. J. et al. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum. Gene Ther. 7, 1545-1553 (1996).
83. Laning, J., Kawasaki, H.,Tanaka, E., Luo,Y. & Dorf, M. E. Inhibition of in vivo tumor growth by the β chemokine, TCA3. J. Immunol. 153, 4625-4635 (1994).
84. Fushimi, T., Kojima, A., Moore, M. A. & Crystal, R. G. Macrophage inflammatory protein 3α transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J. Clin. Invest. 105, 1383-1393 (2000).
85. Vicari, A. P. et al. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J. Immunol. 165, 1992-2000 (2000).
86. Luster,A. D. & Leder, P, 1P-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J. Exp. Med. 178, 1057-1065 (1993).
87. Dilloo, D. et of. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nature Med 2, 1090-1095 (1996).
88. Strieter, R. M. et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 270, 27348-27357 (1995).
89. Arenberg, D.A. et al. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J. Clin. Invest 97, 2792-2802 (1996).
90. Smith, D.R., et al. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J. Exp. Med. 178, 1409-1415 (1994).
91. Richmond,A. et al. Molecular characterization and chromosomal mapping of melanoma growth stimulatory activity, a growth factor structurally related to β-thromboglobulin. EMBO J. 7, 2025-2033 (1988).
92. Takamori, H., Oades, Z. G., Hoch, O. C., Burger, M. & Schraufstatter. I. U.Autocrine growth effect of IL-8 and GROα on a human pancreatic cancer cell line, Capan-1. Pancreas 21, 52-56 (2000).
93. Wang, J. et al. Interleukin-8 inhibits non-small cell lung cancer proliferation: a possible role for regulation of tumor growth by autocrine and paracrine pathways. J. Interferon Cytok. Res. 16, 53-60 (1996).
94. Jordan, N.J. et al Expression of functional CXCR4 chemokine receptors on human colonic epithelial cells. J. Clin. Invest 104, 1061-1069 (1999).
95. Murdoch, C., Monk, P. N. & Finn, A. Functional expression of chemokine receptor CXCR4 on human epithelial cells. Immunology 98, 36-41 (1999).
96. Oyamada,H. et al. CCR3 mRNA expression in bronchial epithelial cells and various cells in allergic inflammation, Int Arch. Allergy Immunol. 120, S45-S47 (1999).
97. Ross, R.Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340, 115-126 (1999).
98. Kol,A. & Libby, P. Molecular mediators of arterial inflammation: a role for microbial products? Am. Heart J. 138, 450-452 (1999).
99. Streblow, D. N. et al. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell 99, 511-520 (1999).
100. Molestina, R. E., Dean, D., Miller, R. D., Ramirez, J.A. & Summersgill, J.T. Characterization of a strain of Chlamydia pneumonioe isolated from a coronary atheroma by analysis of the omp1 gene and biological activity in human endothelial cells. Infect. Immun. 66, 1370-1376 (1998).
101. Boisvert, W.A., Curtiss, L. K. & Terkeltaub, R. A. Interleukin-8 and its receptor CXCR2 in atherosclerosis. Immunol. Res. 21, 129-137 (2000).
102. Abi-Younes, S. et al. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ. Res. 86, 131-138 (2000).
103. Mach, F. et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J. Clin. Invest 104, 1041-1050 (1999).
104. Haque, N. S. et al. CC chemokine 1-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. Circulation 102, 786-792 (2000).
105. Gu, L et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. mol. Cell 2, 275-281 (1998).
106. Gosling, J. et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest. 103, 773-778 (1999).
107. + mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394, 894-897 (1998).
108. Dawson,T.C., Kuziel,W.A., Osahar,T.A, Maeda, N. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 143, 205-211 (1999).
109. Bush, E. et al. CC chemokine receptor 2 is required for macrophage infiltration and vascular hypertrophy in angiotensin 11-induced hypertension. Hypertension 36, 360-363 (2000).
110. Zhou, X., Paulsson, G., Stemme, S. & Hansson, G. K. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J. Clin. Invest. 101, 1717-1725 (1998).
111. Nelken, N.A, Coughlin, S. R., Gordon, D. & Wilcox, J. N. Monocyte chemoattractant protein-1 in human atheromatous plaques. J. Clin. Invest 88, 1121-1127 (1991).
112. Yla-Herttuala, S. et al. Expression of monocyte chemoattractant protein I .in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc. Natl. Acad. Sci USA 88, 5252-5256 (1991).
113. Wilcox, J. N., Nelken, N.A., Coughlin, S. R., Gordon. D. & Schall,T.J. Local expression of inflammatory cytokines in human atherosclerotic plaques. J. Atheroscler.Thromb. 1, S10-S13 (1994).
114. Haley, K.J. et ol. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation 102, 2185-2189 (2000).
115. Schecter,A. D. et al. Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. J. Biol. Chem. 272, 28568-28573 (1997).
116. Ortego, M. et al. Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 147, 253-261 (1999).
117. Romano, M. et of. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab. Invest 80, 1095-1100 (2000).
118. Egashira, K. et al. Anti-monocyte chemoattractant protein-1 gene therapy inhibits vascular remodeling in rats: blockade of MCP-1 activity after intramuscular transfer of a mutant gene inhibits vascular remodeling induced by chronic blockade of NO synthesis. FASEB J 14, 1974-1978 (2000).